Budget impact of Imsidolimab
1 evidence topic · 1 source
Summary
The Dutch horizon scan lists an expected annual cost below €16,500 per patient, while stating that the price is not yet known and that costs may be comparable to spesolimab. This estimate should not be treated as an announced acquisition price or as the results of an imsidolimab budget impact model.